Scholarlink

Background <p>Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) is frequently driven by point mutations such as EGFR T790M. This poses a major clinical challenge that significantly compromises treatment efficacy and patient survival. Conventional detection methods often rely on single-mode signaling and lack built-in validation, which limits their reliability and accessibility, particularly in resource-limited settings.</p> Methods and Results <p>We developed a tri-modal biosensor that integrates alkynyl-modified gold nanoparticles (Alk-GNP) with a molecular beacon (MB) for the multiplexed detection of EGFR T790M. The optimized system simultaneously responds to the target mutation through three distinct modes: photothermal response, colorimetric shift, and fluorescence emission, achieving detection limits of 16.81 nM, 2.41 nM, and 0.80 nM, respectively. The fluorescence modality served as the primary detection mode due to its high sensitivity, while photothermal and colorimetric signals provided real-time cross-validation to enhance overall reliability. Furthermore, the smartphone-compatible photothermal and colorimetric outputs enable portable and point-of-care data analysis, an essential feature of next-generation biosensing platforms.</p> Conclusions <p>This work presents a diagnostic tool that integrates tri-modal signal outputs with built-in cross-validation, which may have implications for guiding treatment decisions in NSCLC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A tri-modal biosensor based on alkyne-functionalized gold nanoparticles and molecular beacon for detection of resistance-related point mutations in epidermal growth factor receptor-tyrosine kinase inhibitors

  • 期刊论文

  • 发表日期：

    2026年5月22日

查看全文
  • Ding Tan,
  • Haixin Long,
  • Ya Wang,
  • Wenjing Lin,
  • Yiling Huang,
  • Haijun Chen,
  • Yu Gao

摘要

Background

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) is frequently driven by point mutations such as EGFR T790M. This poses a major clinical challenge that significantly compromises treatment efficacy and patient survival. Conventional detection methods often rely on single-mode signaling and lack built-in validation, which limits their reliability and accessibility, particularly in resource-limited settings.

Methods and Results

We developed a tri-modal biosensor that integrates alkynyl-modified gold nanoparticles (Alk-GNP) with a molecular beacon (MB) for the multiplexed detection of EGFR T790M. The optimized system simultaneously responds to the target mutation through three distinct modes: photothermal response, colorimetric shift, and fluorescence emission, achieving detection limits of 16.81 nM, 2.41 nM, and 0.80 nM, respectively. The fluorescence modality served as the primary detection mode due to its high sensitivity, while photothermal and colorimetric signals provided real-time cross-validation to enhance overall reliability. Furthermore, the smartphone-compatible photothermal and colorimetric outputs enable portable and point-of-care data analysis, an essential feature of next-generation biosensing platforms.

Conclusions

This work presents a diagnostic tool that integrates tri-modal signal outputs with built-in cross-validation, which may have implications for guiding treatment decisions in NSCLC.